Relevance of JAK2V617F positivity to hematological diseases - survey of samples from a clinical genetics laboratory
Open Access
- 14 January 2011
- journal article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 4 (1) , 4
Abstract
JAK2V617F is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. However, it has also been found in many other hematological diseases, and some studies even detected the presence of JAK2V617F in normal blood samples. This casts doubt on the primary role of JAK2V617F in the pathogenesis of MPNs and its diagnostic value.Keywords
This publication has 21 references indexed in Scilit:
- JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaBlood, 2010
- Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in miceBlood, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseBlood, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemiaHaematologica, 2009
- Transgenic expression of JAK2V617F causes myeloproliferative disorders in miceBlood, 2008
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005